1. Project profile

Modality: ADC based on nanobody

Target : EGFR, cMet

Indications: Colorectal cancer, Pancreatic cancer, Gastric cancer, Lung cancer

Research phase: IND enabling

Cooperation demands: license out

2.Asset VS AZD9592

3. Highlights

High tumor penetration due to the smaller size of ADC
Based on nanobody
Protein surface optimization
Under equimolar toxin , Asset shows stronger toxin delivery capability compared to AZD9592

Asset shows significant efficacy in different CDX and PDX modelsof colorectal cancer, pancreatic cancer, lung cancer;
CDX models (at 3mg/kg):
NCI-H1975: Human lung adenocarcinoma, ~95% TGI
HCT116: Human colon cancer, ~80% TGI
EBC-1 :Human lung squamous cell carcinoma, ~100%TGI
PDX models(at 3mg/kg):
BP0638: Human non-small cell lung cancer,~90% TGI
BP0226: Human pancreatic cancer,~100% TGI